OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

Main Article Content

Ulrike Bacher
Stefanie von Matt
Yara Banz
Behrouz Mansouri
Urban Novak
Thomas Pabst

Keywords

autologous stem cell transplantation (ASCT), diffuse large B-cell lymphoma (DLBCL)

Abstract

Introduction: Autologous stem cell transplantation (ASCT) following high-dose chemotherapy is applied for patients with relapsed/refractory (r/r) DLBCL. However, prognosis of relapsing DLBCL post-ASCT remained poor until the availability of CAR-T cell treatment. To appreciate this development, understanding the outcome of these patients in the pre-CAR-T era is essential.


Methods: We retrospectively analyzed 125 consecutive DLBCL patients who underwent HDCT/ASCT.


Results: After a median follow-up of 26 months, OS and PFS were 65% and 55%. 53 patients (42%) had a relapse (32 patients, 60%) or refractory disease (21 patients, 40%) after a median of 3 months post-ASCT. 81% of relapses occurred within the first year post-ASCT with an OS of 19% versus 40% at last follow-up in patients with later relapses (p=0.0022). Patients with r/r disease after ASCT had inferior OS compared to patients in ongoing remission (23% versus 96%; p<0.0001). Patients relapsing post-ASCT without salvage therapy (n=22) had worse OS than patients with 1-4 subsequent treatment lines (n=31) (OS 0% versus 39%; median OS 3 versus 25 months; p<0.0001). 41 (77%) of patients relapsing after ASCT died, 35 of which due to progression.


Conclusions: Additional therapies can extend OS, but mostly cannot prevent death in DLBCL relapsing/refractory post-ASCT. This study may serve as reference to emerging results after CAR-T treatment in this population.

Downloads

Download data is not yet available.


Abstract 760
HTML Downloads 207
PDF Downloads 703
Suppl. Files Downloads 370